Background Childhood obesity is a growing epidemic worldwide, and it is associated with metabolic complications, such as insulin resistance. Recently, a genetic variation (rs7607980) in the COBLL1 gene has been associated with lower insulin resistance in adults. The aim of the study was to investigate if the association between COBLL1 rs7607980 genetic variant and lower insulin resistance was present early in life.
Introduction
The prevalence of obesity in children is increasing rapidly worldwide. In the United States and in Europe, the prevalence of overweight/obese children is greater than 20% [1, 2] . Overweight/obesity prevalence in Italy mirrors the European proportion, with the highest prevalence of paediatric obesity reported in Southern Italy [3] . Higher BMI is frequently associated with metabolic complications, including insulin resistance [4] [5] [6] . Insulin resistance is characterized by impaired sensitivity of body tissues to the action of insulin, leading to high circulating insulin levels [7] . This condition is a well-known risk factor for the development of type 2 diabetes [7] . Genetic background plays a role in determining insulin resistance in both adults and children [8] [9] [10] . A recent genome-wide association study on insulin resistance carried out in a large sample of adult individuals identified for the first time a common nonsynonymous variant (rs7607980) in the COBLL1 gene to be associated with lower insulin resistance [10] . Importantly, an interaction between this sequence variant and BMI on insulin resistance was observed. The rs7607980 in COBLL1 gene identifies a thymine to cytosine substitution, which results in an asparagine to aspartic acid change at position 939 in the aminoacidic sequence, and the C allele was found associated with lower fasting insulin levels.
It is currently unknown whether this association is present only in adults or it also affects this metabolic trait early in life. Thus, the aim of this study was to investigate the effect of the COBLL1 rs7607980 genetic variant on insulin action in a cohort of children from Sardinia, in Southern Italy. To exploit the interaction between this genetic variant and BMI on insulin resistance, we examined only overweight and obese children.
Materials and methods

Subjects
The study cohort has been previously described [11] . From the initial study cohort, the number of individuals increased from 535 to 878 for a 6-month extension of the enrolment period. Briefly, all the overweight/obese children, from the outpatient clinic of the Pediatric Endocrine Unit for excess body weight, at the Regional Hospital for Microcitaemia in Cagliari, Italy, were consecutively recruited (N = 878) from May 2007 to November 2008. Children with endocrine disorders or genetic syndromes, including syndromic obesity, were not included. None of the subjects were under medication. The study was approved from the Local Ethical Committee, and informed consent was obtained from children or their legal guardians.
Anthropometric measurements
Body mass index standard deviation score was defined according to Italian growth charts in people aged 2-20 years [12] . SDS-BMI >1 and >2 were used to define overweight and obesity, respectively. Pubertal development stages were determined in conformity with Tanner scale [13] , and subjects were divided into two groups: prepubertal (Tanner's stage I: boys with pubic hair and gonadal stage I, girls with pubic hair and breast stage I) and pubertal (Tanner's stages II-V: boys with pubic hair and gonadal stage ≥II, girls with pubic hair and breast stage ≥II).
Clinical and metabolic parameters
Fasting glucose, insulin, total cholesterol, LDL and HDL cholesterol and triglyceride levels were measured in all children. To evaluate insulin resistance, we calculated the HOMA-IR according to the formula: (fasting insulin mU/mL Â fasting glucose mmol/L)/22.5 [14] . After an overnight fast, all subjects underwent an oral glucose tolerance test (OGTT) performed according to clinical recommendations for children [15] . Briefly, 1.75 g of glucose/kg (up to a maximum of 75 g) was administered orally; blood samples were obtained before the OGTT (indicated as 0') and 2 h after the OGTT (indicated as 120') to measure plasma glucose and insulin. Type 2 diabetes was defined according to the American Diabetes Association criteria [16] .
Genotyping of COBLL1 rs7607980
According to manufacturer's instructions, COBLL1 rs7607980 variant was genotyped by TaqMan W assay (Applied Biosystems, Foster City, CA, USA). Primers and probes (FAM and VIC labelled) were supplied directly by Applied Biosystems. The ABI Prism Sequence Detection System ABI 7900HT (Applied Biosystems) was used for post-PCR allelic discrimination by measuring allelespecific fluorescence. Data were extrapolated using the Sequence Detection Software (Applied Biosystems). Genotyping success rate was 100%. 
Statistical analyses
Results
A total of 878 Italian children from Sardinia were examined. The mean age of our study population was 10 AE 3 years, ranging from 2 to 19 years. All subjects were overweight or obese with a mean BMI of 27 AE4 kg/m 2 and a mean SDS-BMI of 1.9 AE 0.5. Children of male gender were 411 (47%), and the proportion of prepubertal individuals was 70%. The rs7607980 genotype and allele frequencies were in Hardy-Weinberg equilibrium (p = 0.999) with a minor allele frequency of 0.18. A total of 874 overweight/obese children were included in the analyses after the exclusion of four individuals with diagnosis of diabetes. Clinical characteristics of nondiabetic individuals stratified by COBLL1 genotypes are shown in Table 1 . The C allele was associated with both lower fasting insulin levels (p = 0.002) and lower HOMA-IR (p = 0.035) after adjusting for age, gender, SDS-BMI and Tanner stage. Lower insulin levels in carriers of the C allele were also observed 2 h after ingestion of an oral glucose bolus (OGTT, see Research Design and Methods, Clinical and metabolic parameters for more details) (p = 0.009, Table 1 ). No other differences in indices of adiposity (i.e. BMI and SDS-BMI) or other metabolic characteristics across genotypes were observed (Table 1) .
Discussion
In the current report, we show for the first time an association between COBLL1 rs7607980 C allele, lower insulin levels and lower insulin resistance in overweight and obese children. In a recent genome-wide association study, Manning et al. showed the association of the rs7607980 C allele with lower insulin resistance in adult Europeans. In this study an interaction between the genetic variant and BMI was observed [10] . Thus, to exploit this interaction and to further elucidate the role of this genetic variant on glucose metabolism, we genotyped COBLL1 rs7607980 variant in overweight and obese children from Southern Italy.
We show that the association between the COBLL1 C allele and lower insulin resistance is present already in young individuals (mean cohort age: 10 years). Notably, the association of the C allele and lower insulin levels is also present 2 h after the ingestion of an oral bolus of glucose, confirming the findings on insulin levels observed in fasting condition.
Impaired insulin action is a major risk factor for type 2 diabetes development. Strategies aiming to reduce insulin resistance are known to lead to a decrease in type 2 diabetes incidence [17] . Because the association between the COBLL1 C allele and lower insulin resistance is present early in life and thus it is likely to persist over time, it would be interesting to examine if the changes in insulin levels are also associated with a reduction of the long-term risk for type 2 diabetes. The identification of genetic variants involved in the susceptibility to insulin resistance may be a valuable tool to stratify the at-risk population, leading to tailored strategies for prevention and treatment of diabetes mellitus. In conclusion, we show for the first time the association between COBLL1 rs7607980 C allele, lower insulin levels and lower insulin resistance in overweight and obese children. Further studies are warranted to examine the effect of this genetic variant on type 2 diabetes susceptibility. 
